Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients

HIV Medicine

Volumn 6, Issue 1, 2005, Pages 37-44

  Iloeje, Uchenna H ^a,f   Yuan, Y ^a   L'Italien, G ^a   Mauskopf, J ^b   Holmberg, S D ^c   Moorman, A C ^c   Wood, K C ^d   Moore, R D ^e  

^a BRISTOL MYERS SQUIBB   (United States)

^b RTI INTERNATIONAL   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d CERNER CORPORATION   (United States)

^e DEPARTMENT OF PATHOLOGY   (United States)

^f NONE   (United States)

Author keywords

Antiretroviral therapy; Cardiovascular disease; HAART; Protease inhibitors; Treatment complications

Indexed keywords

LIPID; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EXPOSURE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; NONBIOLOGICAL MODEL; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TRANSIENT ISCHEMIC ATTACK; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; DIABETIC ANGIOPATHIES; EPIDEMIOLOGIC METHODS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERTENSION; MIDDLE AGED; SMOKING;

EID: 13944282290     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00265.x     Document Type: Article

References (30)

1. Louie JK, Hsu LC, Osmond DH, Katz MH, Schwarcz SK. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. J Infect Dis 2002; 186: 1023-1027.
2. Mocroft A, Brettle R, Kirk O et al. Changes in the cause of death among RfV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16: 1663-1671.
3. Porta D, Rapiti E, Forastiere F, Pezzotti P, Perucci CA. Changes in survival among people with AIDS in Lazio, Italy from 1993 to 1998. Lazio AIDS Surveillance Collaborative Group. AIDS 1999; 13 2125-2131.
4. Rogers PA, Sinka KJ, Molesworth AM, Evans BG, Allardice GM. Survival after diagnosis of AIDS among adults resident in the United Kingdom in the era of multiple therapies. Commun Dis Public Health 2000; 3: 188-194.
5. Vandentorren S, Mercie P, Marimoutou C et al. Trends in causes of death in the Aquitaine cohort of HIV-infected patients, 1995-1997. Eur J Epidemiol 2001; 17: 7-10.
6. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860.
7. Calabrese LH. Changing patterns of morbidity and mortality in HIV disease. Cleve Clin J Med 2001, 68: 105, 109-110, 112.
8. Jacobson S, Shade SB, Borket C et al. Causes and predictors of death among people with HIV in primary care. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, February 2002 [Poster 752-W].
9. Rodriguez B, Valdez H, Salata R et al. Changes in the causes of death in a cohort of HIV-infected individuals: analysis of the last 6 years. 9th Conference on Retroviruses and Opportunistic Infection. Seattle, WA, February 2002 [Poster 755-W].
10. Selik RM, Byers RH Jr, Dworkin MS. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 2002; 29: 378-387.
11. Lewden C, Heripret L, Bonnet F et al. Causes of death in HIV-infected adults in the era of highly active antiretroviral therapy (HAART), the French Survey 'Mortalite 2000'. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, February 2002 [Poster 753-W].
12. Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
13. Vittecoq D, Escaut L, Chironi G et al. Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS 2003; 17 (Suppl. 1): S70-S76.
14. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease. AIDS 2003; 17: 2479-2486.
15. Holmberg SD, Moorman AC, Williamson JM et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360: 1747-1748.
16. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702-710.
17. Klein D, Hurley L, Quesenberry C, Sidney S. Hospitalizations for coronary heart disease and myocardial infarction among men with HIV-1 infection: follow-up through 12/31/03. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Poster 739].
18. Meng Q, Lima JA, Lai H et al. Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am Heart J 2002; 144 642-648.
19. Stein JH, Klein MA, Bellehumeur JL et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104: 257-262.
20. Saves M, Chene G, Ducimetiere P et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37: 292-298.
21. Friis-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 1179-1193.
22. Moorman AC, Holmberg SD, Marlowe SI et al. Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: The HIV outpatient study (HOPS). Ann Epidemiol 1999; 9: 349-357.
23. Anonymous. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486-2497.
24. Cohn JS, McNamara JR, Schaefer EJ. Lipoprotein cholesterol concentrations in the plasma of human subjects as measured in the fed and fasted states. Clin Chem 1988; 34: 2456-2459.
25. Pernerstorfer-Schoen H, Jilma B, Perschler A et al. Sex differences in HAART-associated dyslipidaemia. AIDS 2001; 15: 725-734.
26. Iloeje U, Kawabata H, Wu Y. Age and gender differences in treatment of antiretroviral treatment-associated dyslipidemia among HIV/AIDS patients. Antiviral Ther 2002; 7: L30.
27. Law M, Monforte A, Friis-Moller N et al. Cardio- and cerebrovascular events and predicted rates of myocardial infarction in the DAD study. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Poster 737].
28. Iloeje U, Yu-Isenberg K, Ventura EP, Tuoamri AV, Knoth RL. Treatment of HIV-associated dyslipidemia: a time trend analysis 1998-2001. Antiviral Ther 2002; 7: L29.
29. Stein J, Wu Y, Kawabata H, Iloeje U. Increased use of lipid lowering therapy in patients receiving human immunodeficiency virus protease inhibitors. Am J Cardiol 2003; 92: 270-274.
30. Schackman BR, Freedberg KA, Weinstein MC et al. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med 2002; 162: 2478-2486.